This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Donald Berkowitz, MD

JAMA. 1971;218(7):1002-1005.

Abstract
In 50 hyperlipidemic patients who responded to clofibrate during a three-month trial period, the medication was continued for six to eight years. Eight of the subjects had essential hypercholesterolemia. The remainder had elevations of both the cholesterol and triglyceride levels. Normalization of the serum cholesterol level occurred in each patient and was maintained throughout the entire treatment period. Each of the 42 subjects with hypertriglyceridemia had at least a 25% reduction in those levels; normal values resulted in 38. A reduction in the serum uric acid level and improvement in oral glucose tolerance was also produced in more than 65% of those in whom these were abnormal initially. No evidence of clinical toxic reactions was present in any case.

Author Affiliations
From the Department of Medicine, Temple University Medical School, and the Albert Einstein and Sidney Hillman medical centers, Philadelphia.

Footnotes
Reprint requests to 245 N Broad St, Philadelphia 19107 (Dr. Berkowitz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?